Urinary glucose excretion after dapagliflozin treatment: An exposure‐response modelling comparison between Japanese and non‐Japanese patients diagnosed with type 1 diabetes mellitus
Open Access
- 19 November 2018
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (4) , 829-836
Abstract
Aims: To assess the dapagliflozin exposure‐response relationship in Japanese and non‐Japanese patients with type 1 diabetes mellitus (T1DM) and investigate if a dose adjustment is required in Japanese patients. Materials and Methods: Data from two clinical studies were used to develop a non‐linear mixed effects model describing the relationship between dapagliflozin exposure (area under the concentration curve) and response (24‐hour urinary glucose excretion [UGE]) in Japanese and non‐Japanese patients with T1DM. The effects of patient‐level characteristics (covariates; identified using a stepwise procedure) on response was also assessed. Simulations were performed using median‐normalized covariate values. Results: Data from 84 patients were included. Average self‐monitored blood glucose (SMBG) at day 7, change from baseline in total insulin dose at day 7, and baseline estimated glomerular filtration rate (eGFR) all had a significant effect on 24‐hours UGE, with SMBG being the most influential. Dapagliflozin systemic exposure for matching doses and baseline eGFR was similar between Japanese and non‐Japanese patients; however, higher SMBG and a greater reduction in total insulin dose was observed in the Japanese population. When the significant covariates were included, the model fit the data well for both populations, and accurately predicted exposure‐response in the Japanese and non‐Japanese populations, in agreement with the observed data. Conclusions: There was no difference in dapagliflozin exposure‐response in Japanese and non‐Japanese patients with T1DM once differences in renal function, glycaemic control and insulin dose reductions between studies were considered. Therefore, no dose adjustment is recommended in Japanese patients with T1DM.Keywords
Funding Information
- AstraZeneca
This publication has 17 references indexed in Scilit:
- Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24‐hour continuously monitored mean glucose and fasting β‐hydroxybutyrate levels in a phase IIa pilot studyDiabetes, Obesity and Metabolism, 2017
- Understanding the impact of hypoglycemia on the cardiovascular systemExpert Review of Endocrinology & Metabolism, 2016
- Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2016
- Severe Hypoglycemia and Cardiovascular or All-Cause Mortality in Patients with Type 2 DiabetesDiabetes & Metabolism Journal, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Exposure−response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetesBritish Journal of Clinical Pharmacology, 2014
- Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot StudyDiabetes Care, 2014
- A Model‐Based Approach to Predict Longitudinal HbA1c, Using Early Phase Glucose Data From Type 2 Diabetes Mellitus Patients After Anti‐Diabetic TreatmentThe Journal of Clinical Pharmacology, 2013
- A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjectsJournal of Pharmacokinetics and Pharmacodynamics, 2013
- Pharmacodynamic Model of Sodium–Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational PharmacologyThe AAPS Journal, 2011